Global Digital Therapeutics (DTx) For Mental Health 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI06254023

Publication Date:

June 20, 2025

Pages:

100

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Digital Therapeutics (DTx) For Mental Health market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Digital Therapeutics (DTx) For Mental Health is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Digital Therapeutics (DTx) For Mental Health is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Digital Therapeutics (DTx) For Mental Health is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Digital Therapeutics (DTx) For Mental Health players cover Noom, Teladoc Health, Omada Health, WellDoc, Pear Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淒igital Therapeutics (DTx) For Mental Health Industry Forecast鈥� looks at past sales and reviews total world Digital Therapeutics (DTx) For Mental Health sales in 2024, providing a comprehensive analysis by region and market sector of projected Digital Therapeutics (DTx) For Mental Health sales for 2025 through 2031. With Digital Therapeutics (DTx) For Mental Health sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Digital Therapeutics (DTx) For Mental Health industry.
This Insight Report provides a comprehensive analysis of the global Digital Therapeutics (DTx) For Mental Health landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Digital Therapeutics (DTx) For Mental Health portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Digital Therapeutics (DTx) For Mental Health market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Digital Therapeutics (DTx) For Mental Health and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Digital Therapeutics (DTx) For Mental Health.
This report presents a comprehensive overview, market shares, and growth opportunities of Digital Therapeutics (DTx) For Mental Health market by product type, application, key players and key regions and countries.
Segmentation by Type:
Biology Modifying Drugs
Gene Therapies
Cell Therapies
Segmentation by Application:
Pharmaceutical Companies
Academic and Research Institutions
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Noom
Teladoc Health
Omada Health
WellDoc
Pear Therapeutics
COGNIFIT
Ginger
Propeller Health
2morrow
Canary Health

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size (2020-2031)
2.1.2 Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Digital Therapeutics (DTx) For Mental Health by Country/Region (2020, 2024 & 2031)
2.2 Digital Therapeutics (DTx) For Mental Health Segment by Type
2.2.1 Biology Modifying Drugs
2.2.2 Gene Therapies
2.2.3 Cell Therapies
2.3 Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Type
2.3.1 Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Digital Therapeutics (DTx) For Mental Health Segment by Application
2.4.1 Pharmaceutical Companies
2.4.2 Academic and Research Institutions
2.4.3 Others
2.5 Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Application
2.5.1 Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Player
3.1 Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Digital Therapeutics (DTx) For Mental Health Revenue by Player (2020-2025)
3.1.2 Global Digital Therapeutics (DTx) For Mental Health Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Digital Therapeutics (DTx) For Mental Health Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Digital Therapeutics (DTx) For Mental Health by Region
4.1 Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Region (2020-2025)
4.2 Global Digital Therapeutics (DTx) For Mental Health Annual Revenue by Country/Region (2020-2025)
4.3 Americas Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size Growth (2020-2025)
4.4 APAC Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size Growth (2020-2025)
4.5 Europe Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Country (2020-2025)
5.2 Americas Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Type (2020-2025)
5.3 Americas Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Region (2020-2025)
6.2 APAC Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Type (2020-2025)
6.3 APAC Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Country (2020-2025)
7.2 Europe Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Type (2020-2025)
7.3 Europe Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Digital Therapeutics (DTx) For Mental Health by Region (2020-2025)
8.2 Middle East & Africa Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Digital Therapeutics (DTx) For Mental Health 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Digital Therapeutics (DTx) For Mental Health 麻豆原创 Forecast
10.1 Global Digital Therapeutics (DTx) For Mental Health Forecast by Region (2026-2031)
10.1.1 Global Digital Therapeutics (DTx) For Mental Health Forecast by Region (2026-2031)
10.1.2 Americas Digital Therapeutics (DTx) For Mental Health Forecast
10.1.3 APAC Digital Therapeutics (DTx) For Mental Health Forecast
10.1.4 Europe Digital Therapeutics (DTx) For Mental Health Forecast
10.1.5 Middle East & Africa Digital Therapeutics (DTx) For Mental Health Forecast
10.2 Americas Digital Therapeutics (DTx) For Mental Health Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.2.2 Canada 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.2.3 Mexico 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.2.4 Brazil 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.3 APAC Digital Therapeutics (DTx) For Mental Health Forecast by Region (2026-2031)
10.3.1 China Digital Therapeutics (DTx) For Mental Health 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.3.3 Korea 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.3.4 Southeast Asia 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.3.5 India 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.3.6 Australia 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.4 Europe Digital Therapeutics (DTx) For Mental Health Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.4.2 France 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.4.3 UK 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.4.4 Italy 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.4.5 Russia 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.5 Middle East & Africa Digital Therapeutics (DTx) For Mental Health Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.5.2 South Africa 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.5.3 Israel 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.5.4 Turkey 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
10.6 Global Digital Therapeutics (DTx) For Mental Health Forecast by Type (2026-2031)
10.7 Global Digital Therapeutics (DTx) For Mental Health Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Digital Therapeutics (DTx) For Mental Health Forecast
11 Key Players Analysis
11.1 Noom
11.1.1 Noom Company Information
11.1.2 Noom Digital Therapeutics (DTx) For Mental Health Product Offered
11.1.3 Noom Digital Therapeutics (DTx) For Mental Health Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Noom Main Business Overview
11.1.5 Noom Latest Developments
11.2 Teladoc Health
11.2.1 Teladoc Health Company Information
11.2.2 Teladoc Health Digital Therapeutics (DTx) For Mental Health Product Offered
11.2.3 Teladoc Health Digital Therapeutics (DTx) For Mental Health Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Teladoc Health Main Business Overview
11.2.5 Teladoc Health Latest Developments
11.3 Omada Health
11.3.1 Omada Health Company Information
11.3.2 Omada Health Digital Therapeutics (DTx) For Mental Health Product Offered
11.3.3 Omada Health Digital Therapeutics (DTx) For Mental Health Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Omada Health Main Business Overview
11.3.5 Omada Health Latest Developments
11.4 WellDoc
11.4.1 WellDoc Company Information
11.4.2 WellDoc Digital Therapeutics (DTx) For Mental Health Product Offered
11.4.3 WellDoc Digital Therapeutics (DTx) For Mental Health Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 WellDoc Main Business Overview
11.4.5 WellDoc Latest Developments
11.5 Pear Therapeutics
11.5.1 Pear Therapeutics Company Information
11.5.2 Pear Therapeutics Digital Therapeutics (DTx) For Mental Health Product Offered
11.5.3 Pear Therapeutics Digital Therapeutics (DTx) For Mental Health Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Pear Therapeutics Main Business Overview
11.5.5 Pear Therapeutics Latest Developments
11.6 COGNIFIT
11.6.1 COGNIFIT Company Information
11.6.2 COGNIFIT Digital Therapeutics (DTx) For Mental Health Product Offered
11.6.3 COGNIFIT Digital Therapeutics (DTx) For Mental Health Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 COGNIFIT Main Business Overview
11.6.5 COGNIFIT Latest Developments
11.7 Ginger
11.7.1 Ginger Company Information
11.7.2 Ginger Digital Therapeutics (DTx) For Mental Health Product Offered
11.7.3 Ginger Digital Therapeutics (DTx) For Mental Health Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Ginger Main Business Overview
11.7.5 Ginger Latest Developments
11.8 Propeller Health
11.8.1 Propeller Health Company Information
11.8.2 Propeller Health Digital Therapeutics (DTx) For Mental Health Product Offered
11.8.3 Propeller Health Digital Therapeutics (DTx) For Mental Health Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Propeller Health Main Business Overview
11.8.5 Propeller Health Latest Developments
11.9 2morrow
11.9.1 2morrow Company Information
11.9.2 2morrow Digital Therapeutics (DTx) For Mental Health Product Offered
11.9.3 2morrow Digital Therapeutics (DTx) For Mental Health Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 2morrow Main Business Overview
11.9.5 2morrow Latest Developments
11.10 Canary Health
11.10.1 Canary Health Company Information
11.10.2 Canary Health Digital Therapeutics (DTx) For Mental Health Product Offered
11.10.3 Canary Health Digital Therapeutics (DTx) For Mental Health Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Canary Health Main Business Overview
11.10.5 Canary Health Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.